Observational Study
Copyright ©The Author(s) 2025.
World J Diabetes. May 15, 2025; 16(5): 104576
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.104576
Table 1 General characteristics of the study subjects
Variables1Nondiabetic group
Type 2 diabetic group
n
%
n
%
Demographics
    Age (years)
        < 5043372066.861399142.16
        ≥ 5021502633.141919357.84
        mean ± SD49.567.7955.3410.16
    Sex
        Women39192060.411485344.76
        Men25682639.591833155.24
    SBP (mmHg)
        < 13040822762.931401842.24
        ≥ 13024051937.071916657.76
        mean ± SD125.0018.65133.5018.67
    DBP (mmHg)
        < 8546577871.802167365.31
        ≥ 8518296828.201151134.69
        mean ± SD78.4412.7180.9811.98
Medications
    Anti-diabetic agents00.0033184100.00
    Antihypertensive agents14245321.962148964.76
    Antilipid agents356265.491971059.40
Laboratory results
    FPG (mg/dL)
        < 126648746100.00831925.07
        ≥ 126002486574.93
        mean ± SD91.9410.85170.0070.75
    TC (mg/dL)
        < 20034809853.662216966.81
        ≥ 20030064846.341101533.19
        mean ± SD199.0037.63187.0045.14
    HDL-C (mg/dL)
        M: > 40; F > 5047142472.671757152.95
        M: ≤ 40; F ≤ 5017732227.331561347.05
        mean ± SD56.0416.6947.7315.91
    TG (mg/dL)
        < 15047002972.451741152.47
        ≥ 15017871727.551577347.53
        mean ± SD134.60126.40196.20223.70
    ALT (IU/L)
        Normal53966083.192425873.10
        Above normal10908616.818.92626.90
        mean ± SD25.8631.4031.7634.01
    AST (IU/L)
        Normal57956289.342735082.42
        Above normal6918410.66583417.58
        mean ± SD24.5123.8126.8825.83
Metabolic dysfunctions
    Obesity, kg/m2
        BMI ≤ 3060006092.502624779.10
        BMI > 30486867.5693720.90
    Hypertension
        No37006257.041245737.54
        Yes27868442.962072762.46
    Dyslipidemia
        No20741631.97822724.79
        Yes44133068.032495775.21
Personal history
    Regular exercise
        No35962455.431727252.05
        Yes28912244.571591247.95
Outcomes
    Cirrhosis of liver26970.423851.16
    Hepatic complications14360.222070.62
    HCC8030.121830.55
    Hepatic mortality5170.081340.40
    Mean follow-up period (years) (± SD)6.592.366.782.45
Total648746100.0033184100.00